Prospective Clinical and Biological Database of Cancer Patients Starting Anticancer Immunotherapy Tracking Immune-Related Side Effects Over Time

What this Trial Is About

Researchers are collecting detailed clinical and biological information from patients starting anticancer immunotherapy to better understand immune-related side effects that can affect various organs. The study aims to identify factors that increase the risk of these toxicities and to develop ways to prevent or manage them effectively. This observational study will help personalize future immunotherapy treatments by balancing benefits and risks for each patient. Participants receive immunotherapy drugs such as checkpoint inhibitors including PD-1, PD-L1, CTLA4, and others either alone or with other cancer treatments. Patients are enrolled before their first immunotherapy treatment and followed for up to 5 years or until they stop treatment permanently. The study also collects blood, plasma, serum, and immune cells samples before, during, and at the onset of immune-related side effects. During the study, participants will be regularly monitored through clinical evaluations and biological sample collections to track any immune-related toxicities. Researchers will estimate the incidence of these side effects over 10 years. Data collected will include clinical details and biological markers to support further research on mechanisms causing toxicity. This long-term follow-up helps improve understanding of immunotherapy safety and guides future patient care.

A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE